Radiotherapy (RT) is delivered for purposes of local control, but can also exert systemic
effect on remote and non-irradiated tumor deposits, which is called abscopal effect. The view …

Immune-checkpoint inhibitors (ICIs) have transformed patient care in oncology but are
associated with a unique spectrum of organ-specific inflammatory toxicities known as …

Diagnosis of tumour type allows prognostication and triage for biomarker testing (see the
Supplementary Material Section 3 and Supplementary Figure S1, available at https://doi …

Background Patients with non-small-cell lung cancer (NSCLC) that is resistant to PD-1 and
PD-L1 (PD [L]-1)-targeted therapy have poor outcomes. Studies suggest that radiotherapy …

Immune checkpoint blockade (ICB) improves outcomes for some patients with advanced or
metastatic cancers. Despite demonstrable progress, many patients do not respond to ICB …

Metastases remain the leading cause of cancer-related mortality. The oligometastasis
hypothesis postulates that a spectrum of metastatic spread exists and that some patients …

In the era of cancer immunotherapy, there is significant interest in combining conventional
cancer therapies, such as radiotherapy, with drugs that stimulate the immune system. The …

In the past 10 years, a deeper understanding of the immune landscape of cancers, including
immune evasion processes, has allowed the development of a new class of agents. The …

Local ablative therapies, including surgery or stereotactic radiotherapy (SABR), are
becoming an integral component in the treatment of oligometastatic disease in non–small …

Introduction Previous studies have evaluated stereotactic body radiotherapy (SBRT) in
oligometastatic patients with NSCLC, including multimodality treatment with anti …